MX2016011881A - Medicamento de peptido en polvo seco. - Google Patents
Medicamento de peptido en polvo seco.Info
- Publication number
- MX2016011881A MX2016011881A MX2016011881A MX2016011881A MX2016011881A MX 2016011881 A MX2016011881 A MX 2016011881A MX 2016011881 A MX2016011881 A MX 2016011881A MX 2016011881 A MX2016011881 A MX 2016011881A MX 2016011881 A MX2016011881 A MX 2016011881A
- Authority
- MX
- Mexico
- Prior art keywords
- dry
- medicament
- peptide medicament
- powder peptide
- powder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describe un medicamento de péptido en polvo seco con una concentración no típica de excipiente de carbohidrato, así como también el medicamento para usarse en tratamiento o prevención de una enfermedad o afección, así como también métodos para fabricar el medicamento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14160540 | 2014-03-18 | ||
PCT/EP2015/055481 WO2015140125A2 (en) | 2014-03-18 | 2015-03-17 | Dry-powder peptide medicament |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016011881A true MX2016011881A (es) | 2016-12-05 |
Family
ID=50342194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016011881A MX2016011881A (es) | 2014-03-18 | 2015-03-17 | Medicamento de peptido en polvo seco. |
Country Status (13)
Country | Link |
---|---|
US (1) | US10925924B2 (es) |
EP (1) | EP3062772B1 (es) |
JP (1) | JP6397984B2 (es) |
KR (1) | KR102316762B1 (es) |
CN (1) | CN106456707B (es) |
AU (1) | AU2015233635B2 (es) |
CA (1) | CA2940351A1 (es) |
DK (1) | DK3062772T3 (es) |
EA (1) | EA034620B1 (es) |
ES (1) | ES2665180T3 (es) |
IL (1) | IL247551B (es) |
MX (1) | MX2016011881A (es) |
WO (1) | WO2015140125A2 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170014472A1 (en) * | 2014-03-04 | 2017-01-19 | Apeptico Forschung Und Entwicklung Gmbh | Attenuation of intrapulmonary inflammation |
JP6397984B2 (ja) | 2014-03-18 | 2018-09-26 | アペプティコ・フォルシュング・ウント・エントヴィックルング・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングApeptico Forschung Und Entwicklung Gmbh | 乾燥粉末ペプチド医薬 |
EP3624885A4 (en) | 2017-05-19 | 2021-03-10 | Trudell Medical International | POSITIVE EXPIRATORY PRESSURE DEVICE |
USD874064S1 (en) | 2018-05-18 | 2020-01-28 | Trudell Medical International | Mask |
USD903097S1 (en) | 2018-05-18 | 2020-11-24 | Trudell Medical International | Mask |
USD893806S1 (en) | 2018-11-09 | 2020-08-18 | Trudell Medical Internationl | Mask and shroud |
IL294894A (en) | 2020-05-08 | 2022-09-01 | Apeptico Forschung & Entwicklung Gmbh | A peptide for the prevention or treatment of covid-19 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
US5891679A (en) | 1993-02-03 | 1999-04-06 | N.V. Innogenetics S.A. | TNF-alpha muteins and a process for preparing them |
DE59706180D1 (de) * | 1996-01-24 | 2002-03-14 | Byk Gulden Lomberg Chem Fab | Verfahren zur herstellung von pulverförmigen lungensurfactant-zubereitungen |
DE69937206T2 (de) | 1998-08-14 | 2008-06-19 | Rudolf Lucas | TNF-Peptide und deren Verwendung zur Behandlung von Ödemen |
DE60229979D1 (es) * | 2001-12-05 | 2009-01-02 | Circassia Ltd | |
ES2339954T3 (es) * | 2004-08-06 | 2010-05-27 | Nycomed Gmbh | Composicion que comprende un agente tensioactivo pulmonar y un peptido derivado de tnf. |
MX2008013216A (es) | 2006-04-14 | 2008-10-27 | Mannkind Corp | Formulaciones farmaceuticas de peptido-1 tipo glucagon (glp-1). |
EP2009023A1 (en) | 2007-06-04 | 2008-12-31 | Rentschler Beteiligungs GmbH | Novel peptides and their use for the treatment of edema |
AT507953B1 (de) | 2009-03-05 | 2011-02-15 | Apeptico Forschung & Entwicklung Gmbh | Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität |
EP2397151B1 (en) | 2010-06-21 | 2015-04-22 | Apeptico Forschung Und Entwicklung Gmbh | Treatment of vascular complications of diabetes |
US9616097B2 (en) * | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
AT510585B1 (de) * | 2010-11-18 | 2012-05-15 | Apeptico Forschung & Entwicklung Gmbh | Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase |
EP2679239A1 (de) * | 2012-06-28 | 2014-01-01 | Apeptico Forschung und Entwicklung GmbH | Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit |
JP6397984B2 (ja) | 2014-03-18 | 2018-09-26 | アペプティコ・フォルシュング・ウント・エントヴィックルング・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングApeptico Forschung Und Entwicklung Gmbh | 乾燥粉末ペプチド医薬 |
-
2015
- 2015-03-17 JP JP2017500407A patent/JP6397984B2/ja active Active
- 2015-03-17 KR KR1020167024513A patent/KR102316762B1/ko active IP Right Grant
- 2015-03-17 MX MX2016011881A patent/MX2016011881A/es unknown
- 2015-03-17 EP EP15711471.1A patent/EP3062772B1/en active Active
- 2015-03-17 AU AU2015233635A patent/AU2015233635B2/en not_active Ceased
- 2015-03-17 CN CN201580014154.9A patent/CN106456707B/zh active Active
- 2015-03-17 EA EA201691860A patent/EA034620B1/ru unknown
- 2015-03-17 US US15/126,794 patent/US10925924B2/en active Active
- 2015-03-17 DK DK15711471.1T patent/DK3062772T3/en active
- 2015-03-17 CA CA2940351A patent/CA2940351A1/en not_active Abandoned
- 2015-03-17 ES ES15711471.1T patent/ES2665180T3/es active Active
- 2015-03-17 WO PCT/EP2015/055481 patent/WO2015140125A2/en active Application Filing
-
2016
- 2016-08-30 IL IL247551A patent/IL247551B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP3062772B1 (en) | 2018-01-24 |
AU2015233635B2 (en) | 2019-07-25 |
CN106456707A (zh) | 2017-02-22 |
EP3062772A2 (en) | 2016-09-07 |
ES2665180T3 (es) | 2018-04-24 |
KR102316762B1 (ko) | 2021-10-26 |
EA034620B1 (ru) | 2020-02-27 |
JP2017510633A (ja) | 2017-04-13 |
CA2940351A1 (en) | 2015-09-24 |
WO2015140125A2 (en) | 2015-09-24 |
JP6397984B2 (ja) | 2018-09-26 |
KR20160132021A (ko) | 2016-11-16 |
IL247551B (en) | 2019-08-29 |
DK3062772T3 (en) | 2018-03-26 |
US20170087207A1 (en) | 2017-03-30 |
CN106456707B (zh) | 2020-08-11 |
US10925924B2 (en) | 2021-02-23 |
WO2015140125A3 (en) | 2016-02-25 |
EA201691860A1 (ru) | 2017-03-31 |
AU2015233635A1 (en) | 2016-09-15 |
IL247551A0 (en) | 2016-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016011881A (es) | Medicamento de peptido en polvo seco. | |
MX2022001105A (es) | Anticuerpos anti tigit. | |
GB2544906B (en) | Devices for treating vestibular and other medical impairments. | |
PH12015502042B1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
PH12017500933A1 (en) | Sublingual administration of riluzole | |
HRP20190953T8 (hr) | Hrana za ribe i njezina upotreba u profilaksi i liječenju hemoragičnog sindroma smolta (hss) kod riba iz porodice salmonidae | |
PH12017500934A1 (en) | Sublingual formulation of riluzole | |
PH12017500747B1 (en) | Heterocyclic compound | |
CY1121566T1 (el) | Νευροπροστατευτικο και ενδειξη αυτου | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
MX2016003293A (es) | Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados. | |
MX2015013755A (es) | Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis. | |
MX2019000677A (es) | Células miméticas de células b. | |
MY198753A (en) | Treatment of androgen deprivation therapy associated symptoms | |
MA40574A (fr) | Traitement de maladies fibrotiques | |
SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
TN2016000064A1 (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes | |
UA107743C2 (ru) | Способ лечения аденокарциномы | |
PH12014000104A1 (en) | Therapeutic methods and compositions for treating diabetes | |
EA201692164A1 (ru) | Лекарственное средство для лечения пациентов с тиннитусом | |
IN2014DE00818A (es) | ||
IN2013MU03855A (es) |